Psychedelic Nasal Spray Shows Promise for Depression
A phase 2b trial suggests that a synthetic 5-MeO-DMT nasal spray could offer sustained relief for moderate to severe depression.
Updated on Oct. 26, 2026 in Substance Abuse
Live Poll
Should psychedelic-based drugs be approved as standard treatments for treatment-resistant depression?
A phase 2b clinical trial shows that a mebufotenin nasal spray may help treat moderate to severe major depression. The treatment, a synthesized form of 5-MeO-DMT, demonstrated improved scores in participants across Australia, Europe, and the U.S.
Why it matters
Researchers are investigating this nasal spray to develop more efficient options for treatment-resistant depression. The results provide early evidence that a controlled, single-dose psychedelic treatment could offer sustained relief lasting several weeks.
This phase 2b clinical trial included 193 participants who were randomized to receive 0.3 mg, 8 mg, or 12 mg of the nasal spray. Most patients were ready to leave the treatment session within two hours, with benefits typically emerging within two days and persisting for at least eight weeks.
The players
JAMA
A peer-reviewed medical journal that publishes original research and clinical trial results in various fields of medicine.
The details
The treatment uses a synthesized version of the psychedelic substance 5-MeO-DMT delivered as a nasal spray. Participants received intensive psychological support before, during, and after the dosing session following established protocols for set and setting to manage the psychedelic experience. While the 8 mg dose performed best in this trial, larger phase 3 studies are required to confirm these findings and better understand the potential for adverse effects like severe panic.
Timeline
- 2026-10-26
Clinical trial results were published in JAMA.
2 days post-dose: Antidepressant benefits typically began to emerge.
8 weeks: Duration of observed continued antidepressant benefits.
Health Landscape
This study sits alongside the ongoing clinical research into psilocybin-assisted therapy as another attempt to integrate psychedelic compounds into clinical depression management. It marks an expansion of the current field by testing a different psychedelic compound with a faster-acting delivery method.
These findings are early and represent a preliminary look at a potential future treatment, not a currently available therapy. Any questions regarding new options for managing depression should be directed to a physician who can discuss established, evidence-based treatments.
The takeaway
While these results show early promise for a rapid-acting intervention, psychedelic-based treatments require intensive, medically-supervised settings to ensure safety. For now, focus on maintaining current, evidence-based treatment plans and consult your doctor about any symptoms that remain unmanaged.
What happens next
The 8 mg dose is scheduled to proceed to phase 3 clinical trials, which will involve a larger group of participants to confirm the safety and efficacy observed in this study.
Further reading
Learn more about the latest research on treating mental health conditions at Substance Abuse.
Source note: This article includes information reported by ScienceAlert.
Live Poll
Should psychedelic-based drugs be approved as standard treatments for treatment-resistant depression?
